EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY 4.0

Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain

Jennifer Segar, Kiah Farr, Mary Junak iD, Denise Roe, Sima Ehsani, Mohab Ibrahim, Todd W Vanderah, Pavani Chalasani iD

The Oncologist · 08.07.2026 · 31 (8)

DOI: 10.1093/oncolo/oyag163 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift The Oncologist, online erschienen am 16.07.2026. Verfasst von Jennifer Segar und 7 weiteren Autor:innen. Beteiligte Einrichtung: Next Oncology, Houston, TX, United States. Hauptthemen laut MEDLINE: Analgesics, Opioid, Bone Neoplasms, Breast Neoplasms, Cancer Pain. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 26 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Institutes of Health National Cancer Institute, Comprehensive Pain and Addiction Center (CPAC), University of Arizona Health Sciences, University of Arizona Cancer Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Bone metastases (BM) from breast cancer cause significant cancer-induced bone pain (CIBP). Management of CIBP is primarily with opioids, which have notable side effects. In preclinical models, cannabinoid receptor (CB)2 and CB1 agonists were shown to decrease CIBP and bone degradation. We hypothesized that the addition of CB2/CB1 agonists would decrease opioid requirements in patients with BM.

Methods

We conducted a single-arm study among breast cancer patients with BM on opioid therapy. Patients were treated with 10 mg dronabinol BID for 8 weeks. Our primary objective was to determine the proportion who decreased their opioid use by ≥ 20%. Participants completed the Brief Pain Inventory and the European Organization for Research and Treatment of Cancer quality of life questionnaires before and after treatment. Pre- and post-treatment blood and urine were collected for analysis of biomarkers of bone remodeling.

Results

We enrolled 14 evaluable patients, and 4 decreased opioid use by ≥ 20%, meeting the primary endpoint. Patients reported significant improvements in pain severity, interference scores, quality of life, and insomnia. There was one grade 3 adverse event (dizziness) related to the study drug. A significant decrease was noted in serum C-terminal telopeptide levels with therapy.

Conclusion

Our pilot study shows that the addition of dronabinol resulted in decreased opioid requirements for CIBP. Patient-reported outcomes also demonstrated improved pain and QOL with addition of dronabinol. Our results are promising and warrant further investigation into novel analgesics for CIBP to decrease opioid use. ClinicalTrials.gov NCT03661892

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Analgesics, OpioidBone NeoplasmsBreast NeoplasmsCancer PainAdultAgedFemaleHumansMiddle AgedQuality of LifeDronabinol

Stichwörter der Autor:innen

CB2 agonistsbiomarkersbone metastasescancer-induced bone paindronabinolmetastatic breast canceropiates

Substanzen

Analgesics, OpioidDronabinol

Autor:innen und Institutionen

  • Next Oncology, Houston, TX, United States.
  • Department of Psychiatry, University of Arizona, Tucson, AZ, United States.
  • Department of Surgery, University of Wisconsin, Madison, WI, United States.
  • Mel and Enid Zuckerman College of Public Health, University of Arizona, Tucson, AZ, United States.
  • Department of Biostatistics, University of Arizona Cancer Center, Tucson, AZ, United States.
  • Department of Medicine, College of Medicine, University of Arizona, Tucson, AZ, United States.

ORCID-Profile: Mary Junak, Pavani Chalasani

Förderung

  • NCI NIH HHS
  • National Institutes of Health National Cancer Institute
  • Comprehensive Pain and Addiction Center (CPAC), University of Arizona Health Sciences, University of Arizona Cancer Center

Zitieren

APA

Segar, J., Farr, K., Junak, M., Roe, D., Ehsani, S., Ibrahim, M., Vanderah, T. W., & Chalasani, P. (2026). Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain. The Oncologist, 31(8). https://doi.org/10.1093/oncolo/oyag163

Vancouver

Segar J, Farr K, Junak M, Roe D, Ehsani S, Ibrahim M, et al. Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain. The Oncologist. 2026;31(8). doi:10.1093/oncolo/oyag163

BibTeX
@article{Segar2026,
  author = {Segar, Jennifer and Farr, Kiah and Junak, Mary and Roe, Denise and Ehsani, Sima and Ibrahim, Mohab and Vanderah, Todd W and Chalasani, Pavani},
  title = {Evaluation of dronabinol to decrease opioid use for cancer-induced bone pain},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {8},
  doi = {10.1093/oncolo/oyag163}
}
Kostenlos starten →